Availability: In Stock
Brand: Hilma Biocare 100mg/ml, 10ml/vial
Drug name: Drostanolone propionate
Drug class: Anabolic / androgenic steroids
Use and effective range:
Applications: quality, competition, diet
Anabolic components: moderate
Androgenic components: strong
Dose range and duration of use:
Beginners: not suitable
Hobby: 50-100mg every other day
Professional range: 100mg/day every 1-2 days
Women: 100-150mg / week with restrictions
Application period: 4 – 12 weeks
Active Life: 2-3 days
Drug Class: Androgenic/Anabolic steroid (For injection)
Average Reported Dosage: Men 300-500-mg weekly Women 100-150mg weekly
Water Retention: None
High Blood Pressure: Rare
Liver Toxic: None
Noted Comments: High Androgenic/Moderate Anabolic/Moderate
Anti-estrogenic DHT Conversion: None, DHT derivative
Decreases HPTA Function: Low suppression in most cases
Drostanolone propionate (Masteron) is a highly androgenic injectable steroid that is a synthetic derivative of DHT (dihydrotestosterone). Since DHT does not aromatize to estrogens, there was no noted water retention during administration. If a bodybuilder had achieved a low body fat level, this drug was reported to dramatically improved shape and hardness in muscle tissue while augmenting the vascular appearance of a contest ready athlete. Normally,
Masteron was used only during the last 3-5 weeks before a show as part of a pre-contest stack. In this case, 100-mg was commonly injected every second or third day (2-3 times weekly) by males and at a dosage of 50mg every other day by most women whom reported use.
Additionally, according to available literature, Masteron is quite anticatabolic and anti-estrogenic in nature due to receptor inhibition. So the reported characteristics of this drug do have supportive clinical validation to consider.
Combined with so- called mass steroids, Masteron did aid in a rapid build-up of strength and mass even with its relatively moderate anabolic qualities. However, Masteron was not reported to be the best choice for this purpose by those polled. DHT can promote hair loss and prostate disorders in prone individuals though it is not well documented as to whether or not deviants of the DHT structure can in all case do the same.
Masteron has a receptor binding ability 3-5 times greater than that of testosterone. This means that the drug can hang out longer in androgen receptor-sites and is not easily displaced. The result should be increased AAS activity.
An interesting facet of Masteron is the way it acts as an anti-estrogen. This is due to its ability to compete for the aromatase receptor. As the reader is aware of by now, many AAS are capable of conversion to estrogens. The process is caused by an enzyme called aromatase. (Of course the process of AAS conversion to estrogen is referred to as aromatization) If a drug has the ability to inhibit the enzyme at its own receptor and still act as a powerful non-aromatizing AAS, its interesting and unusual to me.
My personal experiences with this drug have always been favorable with no negative side effects. Additionally I feel that the drug has had value as a sort of AAS moderator. Let me explain this. Masteron has a high SHBG and albumin binding rate.
Since these two hormone binding proteins prevent AAS from mening with their receptors, some would assume this is a bad thing. Masteron is 3-5 times more active than testosterone, so the unbound portion circulating in the blood stream goes a long way. Since the drug binds a higher percentage of SHBG and albumin, any other AAS co-administered with it remains in an unbound/active/free state to a greater extent and is able to induce a greater response. This is an example of noted drug synergy common to protocols reported as most effective yet requiring lower dosages to accomplish a specific result. The implication is that lower dosages of co-administered drugs allowed a decrease in negative side effects.